No Prescription |
 |
 | ||
|
KETOROL Ketonic |
|
| ||
No Prescription » Prescription Drugs 9 » KETOROL Ketonic Ketorolac is used to relieve moderately severe pain usually after surgery. Ketorolac is in a class of medications called NSAIDs. It works by stopping the body's production of a substance that causes pain fever and inflammation.Ketorolac comes as a tablet to take by mouth. It is usually taken every 4-6 hours on a schedule or as needed for pain. If you are taking ketorolac on a schedule take it at around the same times every day. Buy KETOROL Ketonic and other Prescription Drugs 9 products online at Medstore. 770
About KETOROL Ketonic: Product Type: Prescription Drugs 9 KETOROL ( Ketonic Toradol Generic Ketorolac ) KETOROL (Ketonic Toradol Generic Ketorolac) Ketonic Toradol Generic Ketorolac 10mg 200 Tablets Ketonic Toradol Generic Ketorolac KETOROL
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
